PEG-MGF

Coverage status. This page is a placeholder. The full PeptidesBeat pillar guide for PEG-MGF is being researched and is expected to publish before the July 23–24 PCAC meeting. This stub exists so the URL is stable, indexable, and links cleanly into the rest of our coverage.

What We Can Tell You Today

PEG-MGF is one of the twelve therapeutic peptides removed from FDA Category 2 on April 15, 2026. That action cleared the legal compounding path for the compound under valid prescriptions through licensed 503A pharmacies. Final 503A Bulks List placement is pending the July 23–24, 2026 PCAC meeting.

Pegylated mechano growth factor. On the WADA prohibited list — sport-eligibility concerns.

What This Page Will Cover (When Complete)

Our full pillar guide for each compound covers the same standard sections we used for BPC-157 and TB-500:

• What the compound is and how it differs from related molecules.
• What the published research actually shows — and what it doesn’t.
• Current U.S. legal status and the post-April 15 regulatory path.
• Reported safety signals from the available literature and practitioner experience.
• Expected post-PCAC compounded pricing.
• A practical sourcing framework using the 10-point compounding-pharmacy checklist.

Until Then

If you are considering this compound, the same baseline guidance applies as for every peptide on the April 15 list:

1. Work with a licensed prescriber who is qualified to evaluate whether the compound is appropriate for your situation.
2. Source through a PCAB-accredited compounding pharmacy, not the research-chemical channel.
3. Verify your state’s pharmacy board rules before ordering — see the state-by-state tracker.
4. Read the 2026 Peptide Law Playbook for the full sourcing and prescriber-conversation framework.

We will publish the complete PEG-MGF pillar guide here as soon as it is editorially ready. The PeptidesBeat newsletter will alert subscribers when the full profile goes live.